ArticleJournal of the American Heart Association2025
Model for End Stage Liver Disease Excluding International Normalized Ratio Predicts Severe Right Ventricular Failure After HeartMate 3 Implantation in a Contemporary Cohort.
Article in Journal of the American Heart Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The Liver as a Biomarker Organ in Heart Failure: Molecular Mechanisms, Hepatic Scores and Systemic Risk Stratification.International journal of molecular sciences · 2026Review
- Model for End-Stage Liver Disease Excluding INR Is Associated with Poor Prognosis in Elderly Patients with Decompensated Heart Failure.Biomedicines · 2025Article
- The Cardiohepatic Axis in Heart Failure.JACC. Basic to translational science · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRight ventricular failure (RVF) after left ventricular assist devices is associated with significant morbidity and mortality. Therefore, identifying patients at risk for severe RVF is important for clinical decision-making. Current risk prediction models were not developed in contemporary populations with left ventricular assist devices and have limited clinical applicability. In this study, we sought to evaluate whether the Model for End Stage Liver Disease Excluding International Normalized Ratio (MELD-XI) can predict severe RVF after HeartMate 3 implantation.
methodsWe retrospectively analyzed all adult patients who received HeartMate 3 left ventricular assist devices as initial implantation at 2 academic medical centers. We assessed whether MELD-XI is an independent risk factor for severe RVF in multivariate analysis and compared the predictive accuracy of MELD-XI with previously published risk scores. We also investigated the relationship between MELD-XI and markers of RV function and whether MELD-XI was associated with death or pump exchange at 1-year follow-up.
resultsOur study included a total of 246 patients, of whom 74 (30%) experienced severe RVF. After adjusting for relevant covariables, MELD-XI was independently associated with severe RVF (odds ratio [OR], 1.18 [95% CI, 1.09-1.29];
conclusionsAmong patients undergoing HeartMate 3implantation, MELD-XI is independently associated with an increased risk of RVF and in-hospital mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.